https://www.sheshines.org/content/view/432/443/ She addresses healthcare concerns. Dr. Annie De Groot is CEO and founder of EpiVax, Inc.; co-chief editor and founder of Infectious Diseases in Corrections Report; scientific director and founder of GAIA Vaccine Foundation, and interim medical director and founding member of Clinica Esperanza/Hope Clinic. She designs new vaccines for diseases, offers healthcare in Providence and ...

https://www.beloblog.com/ProJo_Blogs/bizblog/2008/09/providencebased-1.html The Montel Williams MS Foundation today announced a grant to Providence-based Epivax, Inc., the first biotech-related company to be awarded a grant from the foundation. Epivax is a privately held company run by Anne Searls DeGroot that is dedicated to the development and implementation of computational immunology tools to benefit the biotechnology industry. The size of ...

EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH), to develop “Epi-13”, a novel therapeutic for the prevention and treatment of Type 1 diabetes, a ...

EpiVax Presents Tolerance-inducing "Tregitopes" at Keystone Conference February 7, 2008 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, presented data at the Keystone Symposium on Tolerance and Transplantation (January 29-Feb 3, 2008), in Keystone Colorado confirming the activity of natural “Tregitopes” to induce tolerance to a wide range of antigens in vitro ...

EpiVax Presents Tolerance-inducing “Tregitopes” at Keystone Conference February 7, 2008 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, presented data at the Keystone Symposium on Tolerance and Transplantation (January 29-Feb 3, 2008), in Keystone Colorado confirming the activity of natural “Tregitopes” to induce tolerance to a wide range of antigens in vitro ...

October 25, 2007 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received funding from the Juvenile Diabetes Research Foundation (JDRF), the world’s largest charitable funder of Type 1 diabetes research, to develop “Epi-13,” a novel therapeutic for the prevention and treatment of type I diabetes, a ...

October 25, 2007 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received funding from the Juvenile Diabetes Research Foundation (JDRF), the world’s largest charitable funder of Type 1 diabetes research, to develop “Epi-13,” a novel therapeutic for the prevention and treatment of type I diabetes, a ...

The National Institutes of Health, National Institute Of Allergy And Infectious Diseases awarded a grant in the amount of $590,912 to EpiVax, Inc. in support of the development of a multi-epitope TB vaccine. This two-year award will allow EpiVax, to pursue pre-clinical studies leading to the optimization of its TB genome-derived DNA vaccine for the ...

PROVIDENCE BUSINESS NEWS By David Ortiz A Providence-based biotechnology pharmaceutical firm that genetically engineers new vaccines has received a $528,313 grant to begin developing a novel treatment for hemophilia. EpiVax Inc. will use the grant, from the National Institutes of Health, to reengineer Factor VIII, a clotting agent in the blood that is deficient in hemophiliacs. ...

February 26, 2007 (Providence, RI)—- EpiVax, Inc, a leader in genome-derived vaccines, announced today that it has received a grant to reengineer botulinum toxin, a protein that is used for cosmetic purposes (the most commonly used brand is known as “Botox”) and which is also used as a revolutionary therapeutic for movement disorders categorized as ...

Providence, RI, December 17, 2004—EpiVax, Inc, a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities, and pharmaceutical companies, has been awarded a BioDefense Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the ...

PROVIDENCE, RI — 04/27/2005 — EpiVax, Inc., a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities and pharmaceutical companies, today announced that it was awarded a $600,000 Phase I Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The grant award ...

EpiVax moves to new facility at 146 Clifford Street including office and laboratory space

Providence, RI, September 8, 2004—EpiVax, Inc, a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities, and pharmaceutical companies, has been awarded a BioDefense Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National ...

EpiVax signs Master Services Agreement with Amgen